Xenon Pharmaceuticals shared its earnings for the third quarter of 2026, showing $1.2 billion in cash.

Nov 9, 2026, 6:01 PM ETResultsRead the original at Benzinga

Good for XENE

Xenon reported significant seizure reductions in 2 key studies and submitted AZK for FDA review. Approval is not assured, but the results and cash for operations into 2029 support a favorable view.

XENE · Xenon Pharmaceuticals

AI read · Good for XENE

The AI's read

The seizure-study results strengthen the case for AZK, and Xenon has described a broad safety record across its epilepsy program. The FDA still needs to decide on AZK, and results from a separate major depression study are due in December 2026. The seizure findings and cash for planned operations support a favorable reading despite those open questions.

Get alerts for XENE

Follow Xenon Pharmaceuticals (XENE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for XENE

Free on the App Store and Google Play, or on the web.